Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727515 | 0.87 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL19981006 | 0.87 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL20215742 | 0.87 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL15850629 | 0.87 | SLC29A1 (0.51) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL17853313 | 0.81 | PRMT5 (0.44) | SLC29A1MEN1KMT2A | |
| SCHEMBL15892160 | 0.81 | PRMT5 (0.44) | SLC29A1MEN1KMT2A | |
| SCHEMBL31685589 | 0.80 | MEN1 (0.69) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL26631287 | 0.79 | SLC29A1 (0.50) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL26631283 | 0.79 | SLC29A1 (0.50) | SLC29A1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL30540707 | 0.78 | SLC29A1 (0.48) | SLC29A1MEN1KMT2AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238217-A1 | AMIDITE COMPOUND AND METHOD FOR PRODUCING POLYNUCLEOTIDE USING SAID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238217-A1 | AMIDITE COMPOUND AND METHOD FOR PRODUCING POLYNUCLEOTIDE USING SAID COMPOUND | RNMT, REV1, TRDMT1 | SLC29A1 819/4885MEN1 447/4885KMT2A 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.